Neurotech International 관리

관리 기준 확인 3/4

현재 CEO에 대한 정보가 충분하지 않습니다.

주요 정보

Peter James Griffiths

최고 경영자

n/a

총 보상

CEO 급여 비율	n/a
CEO 임기	4.1yrs
CEO 소유권	n/a
경영진 평균 재임 기간	2.3yrs
이사회 평균 재임 기간	5.6yrs

최근 관리 업데이트

Recent updates

CEO 보상 분석

Peter James Griffiths 의 보수는 Neurotech International 의 수익과 비교하여 어떻게 변경되었나요?
날짜	총 보상	급여	회사 수익
Jun 30 2024	n/a	n/a	-AU$5m
Mar 31 2024	n/a	n/a	-AU$5m
Dec 31 2023	n/a	n/a	-AU$5m
Sep 30 2023	n/a	n/a	-AU$6m
Jun 30 2023	n/a	n/a	-AU$8m
Mar 31 2023	n/a	n/a	-AU$6m
Dec 31 2022	n/a	n/a	-AU$5m
Sep 30 2022	n/a	n/a	-AU$4m
Jun 30 2022	n/a	n/a	-AU$3m
Mar 31 2022	n/a	n/a	-AU$4m
Dec 31 2021	n/a	n/a	-AU$6m
Sep 30 2021	n/a	n/a	-AU$7m
Jun 30 2021	AU$109k	n/a	-AU$7m
Mar 31 2021	n/a	n/a	-AU$6m
Dec 31 2020	n/a	n/a	-AU$5m
Sep 30 2020	n/a	n/a	-AU$3m
Jun 30 2020	AU$327k	AU$282k	-AU$2m
Mar 31 2020	n/a	n/a	-AU$3m
Dec 31 2019	n/a	n/a	-AU$4m
Sep 30 2019	n/a	n/a	-AU$4m
Jun 30 2019	AU$316k	AU$224k	-AU$5m
Mar 31 2019	n/a	n/a	-AU$4m
Dec 31 2018	n/a	n/a	-AU$4m
Sep 30 2018	n/a	n/a	-AU$4m
Jun 30 2018	AU$106k	AU$97k	-AU$4m

보상 대 시장: Australian 시장에서 비슷한 규모의 회사에 비해 Peter James 의 총 보상이 합리적인지 여부를 입증하기에는 데이터가 부족합니다.

보상과 수익: Peter James 의 보상은 지난 한 해 동안 회사 성과와 일치했습니다.

CEO

Peter James Griffiths (60 yo)

4.1yrs

테뉴어

AU$109,031

보상

Mr. Peter James Lawrence Griffiths, B.Sc. (Hons), has been the Chief Executive Officer of AAT Research Ltd at Neurotech International Limited since October 2020 and served as its Chief Executive Officer an...

리더십 팀

이름	위치	테뉴어	보상	소유권
Alexandra Andrews	Chief Operating Officer	2.2yrs	AU$36.51k	데이터 없음
Gerald Quigley	Director of Public Relations & Director	2.3yrs	AU$136.55k	0.027% A$ 18.3k
Thomas Duthy	Executive Director	2.2yrs	AU$454.40k	0.033% A$ 22.4k
Emanuela Russo	Chief Scientific Officer & Member of Scientific Advisory Board	6.1yrs	데이터 없음	데이터 없음
Carolyn Ellaway	Chief Medical Officer	less than a year	데이터 없음	데이터 없음
Peter James Griffiths	Chief Executive Officer of AAT Research Ltd	4.1yrs	AU$109.03k	데이터 없음
Erlyn Dawson	Company Secretary	5.6yrs	데이터 없음	데이터 없음
Alessandra Gauvin	Joint Company Secretary	no data	데이터 없음	데이터 없음

2.3yrs

평균 재임 기간

경험이 풍부한 관리: NTI 의 관리팀은 경험 ( 2.3 년 평균 재직 기간)으로 간주됩니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
Gerald Quigley	Director of Public Relations & Director	2.3yrs	AU$136.55k	0.027% A$ 18.3k
Thomas Duthy	Executive Director	2.2yrs	AU$454.40k	0.033% A$ 22.4k
Emanuela Russo	Chief Scientific Officer & Member of Scientific Advisory Board	no data	데이터 없음	데이터 없음
Evian Gordon	Member of Scientific Advisory Board	6.1yrs	데이터 없음	데이터 없음
Robert Johnston	Director	less than a year	AU$34.05k	0.081% A$ 55.0k
Mark Davies	Independent Non-Executive Chairman	5.6yrs	AU$61.22k	1.14% A$ 778.3k
David Cantor	Chairman of Scientific Advisory Board (Currently Dormant)	7.9yrs	AU$34.71k	데이터 없음
Tanju Surmeli	Member of Scientific Advisory Board	6.1yrs	데이터 없음	데이터 없음

5.6yrs

평균 재임 기간

경험이 풍부한 이사회: NTI 의 이사회는 경험(평균 재직 기간 5.6 년)으로 간주됩니다.

Neurotech International 관리

관리 기준 확인 3/4

주요 정보

최근 관리 업데이트

Neurotech International Limited, Annual General Meeting, Nov 20, 2024

Less than half of directors are independent

Neurotech International Limited, Annual General Meeting, Nov 15, 2023

Neurotech International Limited Announces Passing of Professor Allan Cripps AO, Non-Executive Director

Less than half of directors are independent

Neurotech International Limited, Annual General Meeting, Nov 30, 2022

Recent updates

Now 22% overvalued

Now 20% overvalued

Neurotech International Limited, Annual General Meeting, Nov 20, 2024

Full year 2024 earnings released: AU$0.006 loss per share (vs AU$0.01 loss in FY 2023)

Less than half of directors are independent

Neurotech International Limited has completed a Follow-on Equity Offering in the amount of AUD 10 million.

Neurotech International Limited has completed a Follow-on Equity Offering in the amount of AUD 10 million.

Neurotech International Limited to Report Q1, 2024 Results on Oct 27, 2023

Neurotech International Limited, Annual General Meeting, Nov 15, 2023

Full year 2023 earnings released: AU$0.01 loss per share (vs AU$0.005 loss in FY 2022)

New minor risk - Financial data availability

Neurotech International Limited to Report Q4, 2023 Results on Jul 26, 2023

First half 2023 earnings released: AU$0.48 loss per share (vs AU$0.003 loss in 1H 2022)

Neurotech International Limited Announces First Patient Treated in Phase I/II PANDAS/PANS Trial

Neurotech International Limited Announces Approval for Additional Phase I/II ASD Trial Extension

Neurotech International Limited Receives HREC Approval for Phase I/II PANDAS/PANS Clinical Trial

Neurotech International Limited to Report Q3, 2023 Results on Jan 30, 2023

Neurotech International Limited Announces Grant of FDA Pre-IND Meeting for NTI164 in ASD

Neurotech International Limited Announces Passing of Professor Allan Cripps AO, Non-Executive Director

Neurotech International Limited Announces Commencement of Patient Randomisation and First Patient Successfully Treats Under New Phase II/III NTIASD2 Clinical Trial for Children with Autism Spectrum Disorder

Less than half of directors are independent

Neurotech International Limited, Annual General Meeting, Nov 30, 2022

Neurotech International Limited, Annual General Meeting, Nov 23, 2022

Neurotech International Limited Reports Further Significant Clinical Improvement at 20 Weeks for Paediatric Autism Patients Treated with NTI164

Neurotech International Limited Announces New Phase I/II Clinical Trial in Children with PANDAS/PANS

Neurotech International Limited Provides Autism Spectrum Disorder Phase I/II Clinical Trial Update

Less than half of directors are independent

Neurotech International Limited Announces Transition of Alexandra Andrews from Chief Executive Officer to a New Position of Chief Operating Officer

Full year 2022 earnings released: AU$0.005 loss per share (vs AU$0.015 loss in FY 2021)

Neurotech International Limited Announces Currently Finalising a Pivotal Phase II/III Clinical Trial Design to be Conducted in Australia

Neurotech International ORDINARY FULLY PAID to Be Deleted from OTC Equity

Neurotech International Limited Announces Executive Changes

Neurotech International Limited Announces Results with NTI164 in Paediatric ASD

High number of new directors

Neurotech International Limited Announces Important Developments Relating to the Study Protocol Assessing NTI164 in Children with Autism Spectrum Disorder

High number of new directors

Neurotech International Limited Announces Successful Developments Relating to Safety and Tolerability of NTI164 and Key Behavioural Parameters That Impact Autism Spectrum Disorder Patients

Neurotech International Limited Appoints Alexandra Andrews as Chief Executive Officer, Effective 8 March 2022

Neurotech International Limited Announces Nti164 Clinical Program Update

Full year 2021 earnings released: AU$0.015 loss per share (vs AU$0.011 loss in FY 2020)

Neurotech International Limited Announces the Continuation of Its Pre-Clinical Program in Neuro-Inflammatory Disease Models In-Line with Research and Development Pathway

Neurotech International Limited Initiates Phase I/II Open Label Study into Autism

Neurotech International Limited has completed a Follow-on Equity Offering in the amount of AUD 2 million.

Neurotech International Limited Announces Strategic Cultivation Partnership with CannaPacific Limited

Neurotech International Limited Announces the Expansion of Its Exclusive License with Dolce Cann Global Pty Ltd

Neurotech International Limited Provides an Update on Clinical Study Program

Neurotech International Limited has completed a Follow-on Equity Offering in the amount of AUD 2.5 million.

Neurotech International Limited Announces Initiation of Clinical Product Formulation Studies

Neurotech International Limited Announces Transition of Peter Griffiths as CEO

Neurotech International Limited Commences Landmark in Vitro Trials of Unique Cannabis Strains

Full year earnings released - AU$0.011 loss per share

CEO 보상 분석

CEO

테뉴어

보상

리더십 팀

평균 재임 기간

이사회 구성원

평균 재임 기간